Illumina, Inc. (ILMN) Earnings Call Transcript & Summary
May 2, 2024
Earnings Call Speaker Segments
Sallilyn Schwartz
executiveGood day, everyone, and thanks for joining the earnings call covering our first quarter of 2024. On today's call, we'll go over the financial results that came out after the market closed, and we'll share some thoughts about what's happening on the commercial and regulatory fronts. Following that, we'll open things up for a question-and-answer session. You can find our earnings release in the Investor Relations portion of our site, illumina.com. Delivering prepared remarks for Illumina today will be Jacob Thaysen, our Chief Executive Officer, along with Ankur Dhingra, our Chief Financial Officer. Jacob is going to walk through where Illumina's business stands right now, and Ankur will take us through the financial results, GRAIL included. Joydeep Goswami, who is acting as an adviser to the company through June 30, will join us afterward for the Q&A. Just a reminder: GRAIL has to be kept and run as a separate, independent entity from Illumina, in line with the transitional measures the European Commission ordered, which blocked our purchase of GRAIL under the EU merger regulation. This call is being recorded, and the audio will be archived in the Investors section of our website. We intend for all forward-looking statements about our financial results and commercial activity made on today's call to be covered by the safe harbor of the Private Securities Litigation Reform Act of 1995. Such forward-looking statements carry risks and uncertainties. What actually happens or what we actually report could differ materially from what's projected or discussed. Every forward-looking statement rests on information available right now, and Illumina has no obligation to update them. For a clearer picture of the risks and uncertainties that might cause actual results to differ, please look at the documents Illumina files with the Securities and Exchange Commission, such as Illumina's most recent Forms 10-Q and 10-K. With that, I'll hand the call over to Jacob.
Jacob Thaysen
executiveThank you, Salli. Hello, everyone, and good afternoon. Ahead of discussing our Q1 results, I'd like to pause and express appreciation to Joydeep Goswami, our former Chief Financial Officer and Chief Strategy and Corporate Development Officer, for everything he has contributed to Illumina across a span of more than 4 years. Per Salli's remarks, Joydeep will remain in an advisory capacity until June so that the handover goes smoothly. I'd also like to extend a welcome to Ankur Dhingra, our new CFO, whom you'll be hearing from in a few moments, and to congratulate Jakob Wedel on being appointed Chief Strategy and Corporate Development Officer. Jakob came aboard at Illumina in November and has played a major part in shaping our long-term strategy planning. All through the quarter, I kept up my meetings with customers worldwide and had the chance to host quite a few of them at our San Diego headquarters, where we talked about fresh approaches to collaborating, innovating, and shaping what their future with Illumina might look like. A number of our customers described how they're expanding their projects using NovaSeq X to access greater discovery power. Harnessing whole genome opportunities in minimal residual disease stands out as one key area of focus. Still other customers are beginning to sequence at greater depth and layering multiomics onto their projects, while some are examining epigenomic biomarkers and methylation as a way to help diagnose and characterize disease; we see a substantial opportunity to grow in multiomics. Customers want more sophisticated solutions to back their work, and we're investigating every avenue for creating value in this area. Our recent purchase of Partec, a specialized multiomics software solution, serves as the building block for our expansion here. Our aim is to work alongside our customers to figure out how we can deliver more sample-to-answer solutions. Illumina sits at the heart of the ecosystem, and we'll keep catalyzing the industry, with even sharper focus on what matters most to our customers. Now to our first quarter results. My comments will center on core Illumina. During Q1, core Illumina revenue came in at roughly $1.06 billion, ahead of what we had expected. Though that was a decent start to the year, we're staying cautious because the global macro environment remains persistently challenging, with customers still constrained when making purchasing decisions. As anticipated, we're watching this unfold across our regions, notably through lower NovaSeq X placements compared with the first quarter of 2023, when we shipped our first X instrument to fulfill a strong preorder book. 3 of our regions saw year-over-year declines. Americas revenue fell 4%, EMEA revenue fell 3%, and Greater China revenue fell 14%. Europe revenue rose 7% year-over-year, though we anticipate a decline in Q2, given last year's strong X shipment in Europe during the second quarter. Even so, the Illumina management team keeps making significant progress executing against my 3 key priorities for accelerating value creation across the company. My first priority, driving our topline, rests on a growing installed base and on helping customers realize the full potential of our instruments. During the first quarter, we delivered another 55 NovaSeq X units, which pushed the total number of X instruments in our installed base past 400. That marks a strong beginning to the year, and we anticipate that momentum will keep growing. We likewise observed encouraging demand for consumables across the quarter, since our customers keep scaling up their operations and broadening their sequencing projects. Thanks to the 25B reagent kit introduced in Q4 along with the 1.5B in Q1, plus the warmly received upgrade to the 10B flow cell, we now offer customers the complete lineup of NovaSeq X products. Also in Q1, we extended XLEAP-SBS chemistry to our mid-throughput customers by launching our P4 flow cell on the current NextSeq 1000 and 2000 instruments. Within the first several weeks following launch, feedback from customers has been outstanding, with reports of reads surpassing specifications for both quantity and quality. Customers appreciate the straightforward migration that allows them to run spatial and single-cell projects, and they are impressed by the accuracy delivered through the onboard DRAGEN. Illumina keeps pursuing strategic partnerships and alliances intended to advance the whole genomics ecosystem. One recent illustration: Pillar Biosciences announced FDA approval for its pan-cancer IBD for general tumor profiling on the Illumina MiSeqDx system. Our partnership with Pillar dates back to 2017, and we are thrilled about this significant milestone. During the quarter as well, Bristol Myers Squibb joined the collaboration we previously announced with Johnson & Johnson innovative medicine to develop our multi-cancer whole-genome sequencing-based molecular residual disease assay, aimed at better understanding disease recurrence. You should anticipate seeing additional activities of this kind moving forward. Now let me shift to my second priority. I remain focused on achieving operational excellence by boosting margin improvement via greater productivity, all while maintaining innovation and growth; my aim has been to align our organization in the manner that best serves our customers' changing needs. In March, we united our marketing and commercial teams within a single customer first global function. I am confident that merging these teams into one global commercial organization will strengthen our agility to serve customers better while producing more durable growth and margins over time. Beyond that, we are concentrating on generating further enhancements across our end-to-end supply chain and are applying a disciplined approach to better our cost structure; during Q1, we put new initiatives in place to adjust pricing throughout our portfolio so that we better cover our global operational cost. We additionally made headway in trimming our real estate footprint by exiting certain facilities in the Bay Area and in San Diego. Such actions contribute to the many ongoing initiatives that will keep supporting our margins and create added flexibility for investment in high-growth areas. We are equally intent on stabilizing our Greater China business. And in Q1, we welcomed Jenny Zheng as Head of region. Jenny brings deep expertise in health care and global organization along with a strong leadership and execution mindset. He's already showing himself to be an excellent leader for our China organization, and he's bringing in adjustments so that our operations become more China-based for China, which will involve strengthening our regional manufacturing and partnerships. Turning to priority number three for me: getting GRAIL resolved as fast as we can. Back in April, we hit a key milestone in the divestiture effort when the European Commission gave the green light to our plan to divest GRAIL. That approved plan allows for both a sale and capital markets routes, and we've been advancing on each of those paths, in line with what the European Commission's divestiture requires; should a capital market transaction occur, we must put roughly $1 billion of capital into GRAIL, which represents 2.5 years of funding according to GRAIL's long-range plan. Cash sitting on GRAIL's balance sheet is part of that figure. We remain on schedule to wrap up the terms of the transactions by the close of the second quarter. I'm looking forward to bringing you further updates before long. All in all, the progress made this quarter leaves me encouraged, and I feel optimistic about fulfilling our initiatives in 2024. I'll now hand things over to Ankur, who will go into more detail about our first quarter results and outlook.
Ankur Dhingra
executiveThanks, Jacob, and good morning to all of you. I'm thrilled to become part of Team Illumina and to help enhance human health by unlocking what the genome can achieve. Making a positive, meaningful difference in health care is something I care deeply about. The part Illumina has played in building and moving the genomics field forward across the past quarter century is something I know well. With that solid base beneath us, I have no doubt we can keep leading, keep serving our customers, and keep fulfilling what genomics promises for patients worldwide. I'd also like to thank Joydeep for the backing he's given me as I settle into this position. These first 2.5 weeks have been excellent. To begin, I'll walk through our segment results for core Illumina and GRAIL, then go over consolidated financial results, and finish with my thoughts on how we currently see 2024. My discussion will cover non-GAAP results, which include stock-based compensation. Please take a look at the GAAP reconciliation of these non-GAAP measures, which you'll find in today's release as well as in the supplementary data posted on our website. Let's begin with our segment financials. Core Illumina first quarter revenue came in at $1.06 billion, a decline of 2% year-on-year, on both a reported and constant currency basis; this top-line result beat what we had anticipated and was mainly attributable to 3 areas: first, robust performance in high-throughput consumables; second, the timing of revenue from certain strategic partnerships; and third, some customers pulling forward delivery of a few NovaSeq X instruments from Q2 into Q1. Core Illumina sequencing consumables revenue reached $698 million, rising 1% year-over-year, largely because of growth in high throughput. Sequentially, NovaSeq X consumables expanded by double digits after the successful launch of the 25B flow cell. Total sequencing GB output across our connected high and mid-throughput instruments rose over 35% year-over-year and increased at a high single-digit rate quarter-over-quarter. Research and applied activity saw benefits as the shift to the NovaSeq X keeps ramping and 25B adoption increased at large core labs. Clinical activity remained driven mostly by the NovaSeq 6000. As a reminder, we view this data as a helpful reference that illustrates the broad activity trends within our installed base and is directionally correlated with revenue over time. Sequencing instruments revenue for core Illumina of $110 million fell 29% year-over-year in Q1 2024. This year-over-year decrease stemmed from both, one, an anticipated drop in mid-throughput shipments as capital and cash flow constraints keep weighing on purchasing behavior and moderate instrument placements; and second, fewer NovaSeq X placements relative to the significant preorder launch-related shipments in the first quarter of 2023; for NovaSeq X, as Jacob mentioned, we shipped 55 instruments in Q1. Core Illumina sequencing service and other revenue of $151 million climbed 27% year-over-year, driven mainly by higher revenue from strategic partnerships and hired instrument service contract revenue on a growing installed base. Now turning to the remainder of the core Illumina P&L. Core Illumina's non-GAAP gross margin came in at 67.1% for the quarter, up 190 basis points from the prior-year period. The main drivers were a better mix in sequencing consumables and our operational excellence programs, which generated cost savings through things like freight and productivity gains. Partly working against that were lower-margin revenue from certain strategic partnerships, along with higher warranty and field service costs. Core Illumina non-GAAP operating expenses reached $491 million, a $23 million decline from a year earlier, largely reflecting lower labor costs from reduced headcount plus ongoing savings tied to our cost containment efforts. Those expenses landed below what we had anticipated, because project spending shifted out of Q1 and into Q2, and because stock-based compensation came in lower thanks to onetime reversals. Taking everything together, core Illumina's non-GAAP operating margin was 20.6% in Q1 2024, versus 17.4% in Q1 2023. Now turning to GRAIL's financial results. GRAIL posted revenue of $27 million for the quarter, a 35% increase year-over-year, mainly on the strength of Galleri adoption. GRAIL's non-GAAP operating expenses came to $197 million, up $24 million from a year ago, primarily because of added headcount supporting commercial expansion plus research and development. Shifting to consolidated results: for the first quarter, consolidated revenue was $1.08 billion, down 1% year-over-year on both a reported and constant currency basis. Non-GAAP net income was $14 million, or $0.09 per diluted share, and that figure absorbed dilution from GRAIL's non-GAAP operating loss of $185 million during the quarter. Non-GAAP EPS beat our expectations, mostly on stronger core revenue and reduced core operating expenses in the quarter. Our Q1 non-GAAP tax rate was 46.4%, versus 27.3% in Q1 2023, with both periods reflecting a significant effect from consolidating GRAIL's operating loss, which grew by $21 million year-over-year. Excluding GRAIL's impact, our Q1 2024 and Q1 2023 tax rates sat in the mid-20s. Our non-GAAP weighted average diluted share count for the quarter was roughly 159 million. Now to consolidated cash flow and balance sheet items for the quarter. Operations provided $77 million in cash flow. Capital expenditures totaled $36 million, free cash flow was $41 million, and no common stock was repurchased. We closed the quarter with about $1.12 billion in cash, cash equivalents and short-term investments. Let me move to 2024 guidance. As a reminder, Illumina is working as fast as it can to resolve GRAIL, and given the uncertainty about the exact timing and impact of the GRAIL divestment, the company is centering its 2024 financial outlook on core Illumina. Our guidance builds in no effect from a possible GRAIL divestment during 2024; once the divestment is complete, we will offer non-GAAP EPS guidance for 2024; we're pleased that our Q1 results surpassed our expectations on both topline and margins; we've also observed the seasonal rebuild of our total performance obligations, or backlog, which rose over 20% relative to the close of Q4. Meanwhile, we continue to observe no meaningful uptick in either the broader economy or our China operations, and we're keeping an eye on how a stronger U.S. dollar is affecting us. Though consumables have shown encouraging momentum in the early part of the year, that gain is being counterbalanced by capital limitations that keep holding back purchases of instruments. Because of this, we're reaffirming our 2024 full-year core Illumina revenue outlook of roughly level with 2023, along with a non-GAAP operating margin of about 20%. Our margin projections still incorporate gains from improved gross margin and tight cost control, such as a smaller workforce, balanced against the return of performance-based pay to normal levels and inflationary pressures; for Q2 of 2024, we anticipate core Illumina revenue between $1.072 billion and $1.084 billion, which represents a decline of 6.5 to 7.5 percentage points versus the prior year. That year-over-year drop stems mainly from fewer NovaSeq X instrument shipments, since we cleared a substantial backlog early last year after the launch. Taken at the midpoint, this outlook implies a $22 million rise sequentially over Q1 of 2024; for the second quarter, we project core Illumina non-GAAP operating margin near 18%, driven by a seasonal bump in operating expenses during Q2 relative to Q1, largely from higher stock-based compensation costs tied to the timing of equity grants; we also anticipate a rise because certain project spending is moving from Q1 into Q2; having said that, I'll hand things back to Jacob now for his closing comments. Thank you.
Jacob Thaysen
executiveThank you, Ankur. Ahead of wrapping up and turning things over for questions, I want to say a few words about the strategy update event we have coming. The leadership team here at Illumina has been taking a fresh look at where we're headed, the road map and the initiatives meant to get us there, and the profitable growth we think that can deliver. Building the genomics ecosystem and keeping a sharp focus on customers in a space that's getting more competitive will remain central to what we do. At the heart of this sits our aim of making customers the heroes in their own labs; whenever we sit down with a customer, we're listening closely to grasp what's required for them to unlock the complete potential of their Illumina instruments, and we're placing their priorities at the center of our strategy. You'll see us keep creating additional sample-to-answer solutions that support the genomics and multiomics ecosystems; our open platform approach stays in place, and we'll keep pushing the innovation customers depend on to thrive and that Illumina is recognized for. For a long time, Illumina has set the standard in NGS. The hands-on strategic support we provide to customers around the world, our extensive experience and know-how spanning numerous research and clinical markets, and our technology road map stretching a decade out leave us well positioned to keep leading this industry and to help our customers advance human health. It's a pleasure to share that we'll walk you through our full strategy work at a virtual event this fall. More details will come over the next few months. We appreciate you being here. I'll ask Ankur and Joydeep to come join me now for Q&A.
Doug Schenkel
analystJacob, I'd like to begin at a high level with something that sort of builds on what you announced earlier, and after that I have a particular cleanup question about the quarter. So to start, it's difficult to accept, but at this point we are a bit past — I believe it's 8 months since you took over as this company's CEO. Looking from the outside, we can see the adjustments you're beginning to implement in leadership, across the wider organization, and in heading toward a resolution regarding GRAIL. Even so, plenty of uncertainty remains around things such as, first, how you see Illumina's growth profile over the long term, particularly considering the unclear competitive situation and what market elasticity might look like. Second, which operational targets would be sensible? And third, in the end, whether the business, as it stands right now, is set up to play offense. Could you share at least a bit more with us today about where things stand as you move from collecting data and assessing the business toward perhaps staking out some positions on the company's medium- and long-term outlook when it comes to growth and operating margin? I realize that was a great deal, but allow me to slip in the math-related follow-up about the quarter. It appears high throughput sequencing consumable revenue rose in the low to mid-teens. Is that accurate? If it is, what does that suggest to you regarding changing competitive dynamics and questions about elasticity?
Jacob Thaysen
executiveWell, Doug, many thanks. That was quite a lengthy question, and I believe congratulations on your birthday as well. So I'll try my hardest to address the first one. And actually, I think I'm only slightly past 7 months in this role. So perhaps I ought to get another month before we truly pose that question. Still, without a doubt, I'm devoting — I keep devoting considerable time to our customers and to our employees. Each time I head into the R&D building and discover fresh innovations we're working on, I get excited. There's so much taking place at this company. At the same time, we're also directing a great deal of effort toward examining, naturally, where — how are we — which way are we steering Illumina from here. And I believe we touched on a bit of that during my prepared remarks, namely that we perceive many opportunities in genomics, but now with the X having launched, and we already see substantial elasticity there, since numerous customers are employing it to move into single cell, into spatial, and to run larger and larger programs with deeper and deeper analysis. This isn't something coming later. It is already occurring today. But clearly, at the same time, we are working through that shift in price point. Naturally, we anticipate that elasticity will be a significant benefit to us across the coming timeframe. So even though I'm not prepared to reveal what our longer-term overall growth trajectory might look like, you can count on the fact that our outlook on Illumina's future expansion remains positive. Next, as I believe was evident during Q1, we are deeply committed to further widening our margins. And I'm quite happy with the effort our team here has put in and with the gross margin improvement we achieved this quarter. I think that stands as proof of our determination to keep pushing higher. Nor do I see any obstacle preventing us from lifting margins over the coming timeframe back to the historic levels we've reached before. That said, I'd prefer to hold off a bit longer until everything is properly aligned strategically — including both our growth algorithm and our cost structure algorithm — before we go out and disclose the specifics. Still, at the core, I genuinely think Illumina holds a tremendous opportunity to remain — and to keep doing what we've accomplished over the past decade — as the leader of the genomics industry, positioned at the center of the ecosystem, supporting our customers. Yet going forward, customer expectations differ from what they once were, demanding a sharper focus on end-to-end workflows, along with fresh innovations in the multiomic space, which we are strongly dedicated to. So that's where things stand for me at the moment. I think perhaps at this point — Joydeep could assist us somewhat with the consumable question.
Joydeep Goswami
executiveRight, and once more, Doug, happy birthday. When it comes to consumables, we saw the strong growth we anticipated with X consumables, and the revenue from X consumables offset the growth in X consumables revenue — that offset the decline we expected in 6K consumers, correct? So that's a solid element. We're also observing very strong growth in sequencing activity, driven by X and X customers, right? So this is genuinely positive, and it supports much of what Jacob discussed regarding new applications or expanded applications in clinical and research, correct? So that's exciting for us, and we anticipate it will keep going as the 25B flow cell becomes more widely adopted and more routinely used in our customers' regular activities.
Puneet Souda
analystLet me spend a moment on the mid-throughput portion. I'd simply like to get a sense — could you tell us how much growth occurred in that mid-throughput area, for consumables and, even more significantly, for instrumentation? There are — questions keep growing, since customers and core labs that may not own an X or a 6K are adopting a rival platform, given that its price is lower — I mean its cost per gigabase is lower, roughly half of what XLEAP and the NextSeq cost. So I'm just curious, could you say a little more about what's going on in that portion? And what's your approach to it?
Jacob Thaysen
executiveYes. I appreciate that, Puneet. To begin with, growth details for the mid-throughput portion aren't something we're giving out. Still, let me attempt to respond to a few of your points regardless — we are, naturally, strongly dedicated to mid throughput, and the X's chemistry arriving now on the 1K, 2K has me genuinely thrilled. It's just a handful of weeks since launch, yet we've observed, as I've also said previously, enormous enthusiasm among our customers, because no new instrument is required — largely through a software upgrade, you're able to add — you're able to employ the new flow cells, and thereby obtain better quality scores, greater capacity, and naturally, at a favorable price point. So many of our customers feel very excited about it, and it truly positions us as highly competitive there. Having said that, you're correct, rivals exist; and incidentally, we regard competition gravely across all our segments, yet mid-throughput is plainly the place with more activity — more competitive activity — than perhaps other areas. We're observing that chiefly in China as yet. Yet elsewhere around the world, it's happening too. Still, we'll keep innovating here. The XLEAP, as I noted, represented a solid move in that direction; yet this is a space where we'll keep competing. And beyond that, we intend to battle for each and every market share point available.
Joydeep Goswami
executivePerhaps I could add — okay, so two points. First, we keep observing expansion in consumables. That means elasticity within the mid-throughput portion; that's the first one. Second, as we mentioned when we discussed our budget for the year, we had already factored in a particular degree of competition, and what the market is showing us matches what we had predicted; and once more, I want to stress that a portion of the guidance we provided from that throughput took into account the macroeconomic headwinds we had anticipated encountering throughout this year, and we — in fact, those have materialized, correct? So once again, it aligns with what we had communicated to you.
Vijay Kumar
analystAnkur, good to have you. My initial ask — the first thing I want to cover — concerns the guidance you've given. Jacob, perhaps you could weigh in too, correct? Looking at it sequentially, core revenues rose roughly $30 million-ish. Is the consumables segment responsible for all of that? I believe you said you observed better consumable pull-through on the X as the quarter went on. So perhaps some detail on what the exit rate looks like and what's fueling that gain?
Jacob Thaysen
executiveYes. Ankur can definitely add his thoughts here as well, but strength was actually evident across the whole quarter. This wasn't something concentrated in the final few weeks. Yet we keep seeing customers take up the X consumables, and now we have a complete portfolio spanning the 25B, the 10B and the 1.5B. We're seeing many more applications arrive from our customers. So it really has come genuinely from the X, as Joydeep mentioned earlier too, that improvement has shown up. On top of that, we have also — so the beat was quite pleasing on the consumables side. But our BD revenue growth has also shown up. Certain partnerships have moved faster. And we're simply thrilled about that, since working alongside our partners to keep developing is a major piece of our strategy as well. So that contributed to our performance too. Ankur, anything further to add?
Ankur Dhingra
executiveRight. I believe that was pretty thoroughly addressed, thanks. The one point I'd tack on in particular is that the quarter-over-quarter growth in business we're projecting and using as the basis for guidance is coming from instruments as well as consumables, so we anticipate that favorable momentum to keep going in both of those.
Dan Brennan
analystAnkur, great to have you with us. Perhaps a question about multiomics and a few of the fresh offerings that Jacob has mentioned, which have also appeared in the Illumina proxy. Could you share some detail, perhaps beginning with the SomaLogic partnerships? Is that the multiomic enthusiasm you're conveying? After that, any further detail you can offer regarding sample-to-answer and the additional newer areas you intend to investigate, and on timing — when should we expect an update? Will that come at Investor Day? Or how should we consider the possible opportunity for Illumina?
Jacob Thaysen
executiveSure, absolutely. Thank you, Dan. You're completely correct. Broadly speaking, I'm enthusiastic about the role sequencing can have in multiomics. I'm also enthusiastic about how we might assist partners and customers in energizing that market. That applies across every multiomic field, when you examine them. Naturally, in the near term, we're very enthusiastic about our connection with SomaLogic and the direction we can take with proteomics. We remain in early access. Therefore, 2024 will be the year when we move forward with a small number of customers and genuinely work to ensure we fully grasp the potential, yet feedback from customers thus far has already been extremely favorable. So I'm definitely enthusiastic about that. However, we'll keep examining possibilities for us to engage even more powerfully in multiomics moving forward, across every opportunity available, both through internal efforts and, naturally, alongside our partners in the market. When you examine end-to-end workflows, I believe that represents a truly excellent opportunity, as I've said previously, since I observe customers clearly seeking the finest technology, yet they also seek simplicity of use. That concerns not just the sequencing instrument itself, but the path from sample to answer. The more automation we achieve, the more simplification we achieve in sample preparation and, naturally, in informatics as well, the more I believe we can guarantee that our customers devote their time to where they generate the greatest value. So we'll discuss this further, as you noted, during our strategy update. I believe Illumina has a tremendous opportunity to address entire workflows and build excellent applications for our customers.
Dan Arias
analystThis is Paul, filling in for Dan. I believe we just have one question from our side. Regarding POPSEQ, might we get some thoughts on that? It appears that every one of us has witnessed a certain amount of budget strain. There has been some news flow regarding recent reductions. Does that pose any danger to the consumables projection for this year? And perhaps conversely, over in Europe with genome of Europe, there has been some discussion about that gaining momentum? Could that be something where you might see heightened activity in 2025 that would be significant?
Jacob Thaysen
executiveI believe on the whole, we have — should you examine the longer term, we are — long horizon or midterm horizon. I am extremely enthusiastic about the PopGen — not just for PopGen but what it truly represents regarding <<inaudible>> genuinely investigating large genomic studies to — ultimately to integrate into the healthcare system. And we have over 30 programs underway at present, and we have no fewer than an equivalent count in the pipeline for prospects in the future. However, we are not relying on any single individual program; so it is evident with these large programs, where you have sovereigns who must establish the systems and budgets and so forth that there is a bit of give and take in that. And therefore, we are not actually planning and constructing our budgets founded on individual programs. So I do not anticipate that any of them are having a major effect on our either '24, '25 opportunity. But clearly, we are endeavoring to invigorate the market out there.
David Westenberg
analystI'd like to begin by picking up where Puneet left off regarding the mid-throughput segment. In what ways has XLEAP been useful there — or what benefits do you expect it to deliver? And Joydeep, I believe you brought up the existence of some elasticity in that area. My sense is that things are somewhat murkier when it comes to the X department — you clearly observe the entire genome, and you notice far more activity around single cell work. Could you restate that elasticity once more and explain how it can be kept from turning into a race to the bottom, especially since, as you noted, the competitor is competing on price in that space? Turning to high throughput, you stated that you anticipate order rate momentum will strengthen. Does that reflect orders actually sitting in the book? Are these orders arriving extremely late in the cycle, or is it simply expectations about budgets? In other words, is there any way you could take us through this and make it clearer for us?
Jacob Thaysen
executiveSure. Thanks. Allow me to add some additional detail regarding mid-throughput and what we're truly observing — XLEAP's chemistry, as I mentioned, has really 3 dimensions to it: it delivers sequencing of high quality, yet it also provides greater capacity at a reduced cost. That gives customers a real chance to accomplish more with their sequences. Consequently, we're also noticing customers who had been considering a move into single cell or perhaps spatial work but believed they either couldn't afford it or couldn't manage it given the capacity levels or the cost positioning that existed before — that space is now accessible to them. So once again, I believe we're witnessing an elasticity dynamic that will unfold across the coming period. Ultimately, customers genuinely want to partner with the innovators in this field; and I believe XLEAP chemistry is simply one more proof point that we keep innovating across every one of our segments; and so even though the current environment has likewise been affected by macro conditions, I'm honestly quite enthusiastic about what XLEAP chemistry will accomplish for us in the period ahead and about the new applications it will unlock, including within mid throughput. As you pointed out, plenty is happening in high throughput as well, yet we're observing a number of the same developments in mid throughput.
Joydeep Goswami
executiveYeah, I’d like to jump in and build on Jacob’s points. Keep in mind that XLEAP was designed so our customers could keep using instruments they already have in the field and, with just a minor software update, achieve higher output along with improved accuracy and performance. That really showed up clearly when we launched in Q1. I also want to stress that you’re seeing the elasticity right away, especially in research. A lot of what Jacob mentioned—multiomics, single cell, spatial work—tends to be done first in research on mid-throughput. Because of our innovation and technical superiority, we’re also still seeing that we can hold a price premium compared with what competitors offer in the market. So much of that is continuing, and it encourages us. The macroeconomic factors are present, but they’ll finish at some point, and we do expect that when that happens, some of the cash constraints our customers face will ease.
Jacob Thaysen
executiveRight. Then regarding your inquiry about X order trends, what I'd say is this: to begin with, we have observed X orders rising compared to the same period last year. That certainly gives us encouragement, and as you're also aware, we do anticipate gaining momentum as the year progresses. So right now, all we expect is for things to improve. This is particularly true given that many customers who purchased 1 or perhaps 2 Xs have completed validation work on it. And we're beginning to witness these larger orders arriving, reaching as many as 10 instruments at once, so I believe that momentum will carry on throughout the year as well.
Joydeep Goswami
executiveHowever, Dave, this isn't founded on some mysterious fresh budget item, correct? To say it again, as we see it, we have anticipated that the macroeconomic situation would carry on just as it currently stands.
Subbu Nambi
analystYou restated your outlook for how much the core sequencing business would grow in 2025. And I'm sorry if I overlooked this, but is your expectation still that consumables and instruments will have the same mix? Or has that anticipated path shifted somewhat?
Ankur Dhingra
executiveYeah. Excellent question. Ankur here. You're correct that we restated our full-year outlook, covering both revenue and operating margin. In fact, we've gotten off to a strong beginning this year with how Q1 turned out, which certainly takes some of the risk out of the picture. Overall, we will reaffirm our outlook. So the framework remains in place. The — and you've observed how Q1 went. To give a bit more detail on that, when you consider things from a first-half versus second-half angle, and so on, our instrument growth rates, because of how X shipments went in 2024, those rates fluctuate across the year between the first half and the second half, whereas consumables, as they're beginning now, ought to follow a steadier pattern. We observed solid pricing. We also saw solid pull-through in the quarter. So at this point, we are simply reaffirming the overall outlook for the year.
Sung Ji Nam
analystI'd also like to extend a welcome to Ankur and congratulations, plus thanks to Joydeep. One brief question regarding where things stand with the jurisdictional appeal in Europe — and if that matter isn't resolved prior to the close of 2Q, would you still be giving us your final divestiture terms?
Jacob Thaysen
executiveYeah, appreciate that question. Broadly speaking, as you're aware, we're pushing ahead with GRAIL as quickly as possible, and we've made a commitment to deliver that insight by the conclusion of Q2. From my perspective right now, there's nothing at all — no information — standing in the way of that. That said, we have no idea when word from the ECJ will arrive. And like I mentioned, we aren't holding things up waiting on it. Should it land ahead of Q2, the timeline genuinely stays the same: end of Q2.
Tejas Savant
analystIf I could, Jacob, I'd like to run through a couple of quick clarifications regarding the high-throughput side of things. Regarding the 25B flow cell, it seems you're seeing genuinely solid momentum there. Could you update us on that 40% figure you mentioned previously, along with the X customers who picked up 25B? What does that number look like now? Next, is there anything new on how far along high clinical customers are in their X validation efforts? Are there any metrics you can offer? Or should we view production workflows and clinical ramping as primarily a 2025 phenomenon? Then, finally, on the topic of surplus high-throughput capacity — that's a factor that surfaces from time to time. Is it beginning to affect purchasing choices among these high-throughput customers at all? With Ultima also entering the market here, I'm just wondering about the macro headwinds versus the absorption of that added high-throughput capacity, given the NovaSeq X and the 25B launch, plus the competitive landscape?
Jacob Thaysen
executiveYes. On the whole, I'd say we're quite happy with the direction the X and the 25B consumers are heading. And as of now, we are — roughly half of our customer base has — is utilizing the 25B flow cell. So that's genuinely thrilling for us, and that momentum gives us encouragement. I believe a large number of our clinical customers, as I understand it, are still running the bulk of their their assays on the 6K. We're monitoring each of them quite closely and observing their status and their progress from validation and when they move into production; so we possess deeper that insight. I don't think we at this stage, we are prepared to disclose that. But we have a very solid grasp of it. Yet I still believe there is — that is — plenty of them are still progressing through the validation, and afterward they will add on one by one of new kinds of assays that probably carry higher, deeper depth or more insights for — in these assets that they had on the 6K.
Mason Carrico
analystApologies if you've already covered this — I hopped on the call a little late. Can you bring us up to speed on how win rates are trending outside China for the most recent quarter? My recollection is that you described them as having stabilized during Q3 and Q4. Has that steadiness carried over into 2024 up to now? Then, for my second question, is there anything you can share about the composition of incoming orders — specifically regarding 6K upgrades, fleet expansions, new customers, and customers who are new to high-throughput?
Jacob Thaysen
executiveWell, on the whole, naturally we monitor our win rate position very carefully. As we've said, it has stabilized, and we review it on a routine basis, making sure we keep sharpening our approach so we can perform even better. Honestly, I'm pleased with how things are going out there. That said, we obviously watch this extremely closely. Like I've said previously, we treat competition as a serious matter. We're pulling out all the stops to make sure our customers feel very well supported and that they achieve success in laboratories, which ultimately, over time, is the recipe for winning that makes us the partner customers prefer; and regarding the order mix, I'm not sure whether we typically disclose that kind of information. Still, I'd say that at this stage, there are definitely more research customers who have shifted to the X. We've also observed customers owning multiple 6Ks who are beginning to make the move to the expert. I'd characterize the bulk of them as still being in the transition phase.
Rachel Vatnsdal Olson
analystI'd like to dig a bit into the instrument placement figure for the X this quarter. You brought up 55 placements, yet you also pointed out that a number of locations had been pulled forward from 2Q into 1Q. So to start with, could you quantify exactly how many placements got pulled forward? And then on full year dynamics, you keep emphasizing that the macro backdrop is still tough; we've really observed that throughout the sector this quarter; but given that assumption, can you share your most recent assumptions regarding placements for the year?
Jacob Thaysen
executiveYes. Overall, I would say, as we stated, we're — nothing was pulled forward by us. There were — certain customers asked to move things ahead since some of their programs were progressing more quickly than expected. But it was only a handful, so expectations didn't really shift much. Still, in the end I appreciate that, because it demonstrates there's a lot of interest out there and a customer who has already bought one now wants to speed up their transition into the X. So we are — so that makes me excited. Right now, we aren't giving a number, but we know that when we came into 2023, we had an extremely, extremely strong backlog, of course, as you're aware, entering 2023. So — and because of that, 2023 was a very strong placement year of high throughput. So we do expect to come in lower than that, as we also said in our original guidance. But we haven't — we are unable to provide — or we're not — at this point, we're not really altering our expectation for the year.
Ankur Dhingra
executiveRichard, the one point I’d make for your benefit is that our topline performance came in significantly ahead of what we had anticipated. In relation to that overall result, or the amount by which we exceeded expectations, only a limited share — roughly 1/4, perhaps — originated from those customers who requested that the instrument be delivered sooner. So that phenomenon accounted for a comparatively modest piece of it.
Patrick Donnelly
analystCould you walk us through what happened with margins? In 2Q, they clearly came down somewhat. You all noted there may have been some product cost involved. But could you provide additional detail on what increases in spending during 2Q, and then how that metric ought to be viewed as the year progresses? And then, a small follow-up regarding service revs — those landed considerably above our expectations. Fleshing out what occurred there too would be quite useful.
Ankur Dhingra
executiveAbsolutely, happy to. That's a good question. Let me take both of them. This is Ankur speaking. Regarding OpEx, as I mentioned during my prepared remarks, indeed spending steps up between Q1 and Q2, driven mainly by 2 factors. One involves simply the scheduling of our merit increases within the annual stock branch cycle. As a result, the complete effect of that expense hits us during Q2. That one is seasonal — it typically occurs each year at the company. So approximately half of the quarter-over-quarter rise in OpEx stems from it. The remaining half generally concerns certain project-related spend that we've deferred, either deferred to Q2, or there are milestones falling in Q2 that are going to take place. Looking ahead, when you consider your P&L for the remaining portion of the year, my expectation is that overall operating margin performance keeps getting better on a sequential basis each quarter. Thus Q3 exceeds Q2, and afterwards Q4 exceeds Q3.
Joydeep Goswami
executiveNow regarding the service side?
Ankur Dhingra
executiveAnd turning to services, once again we saw quite robust growth overall — roughly 27% year over year — made up of 2 primary pieces. One portion, a bit under half, stems from services for particular pharma customers, and the timing of that landed in the quarter; so that accounted for under half, while approximately half of that growth comes simply from the outstanding results in our core instrument services business.
Joydeep Goswami
executiveGiven how many instruments we got out there, that's what you'd anticipate. And building on what Ankur said, correct? We anticipated stronger gross margin results and we achieved them, right? That ought to give our operating margin a lift. We anticipate that gross margins will keep performing well. So that's going to be a help to us, and as revenue increases too; and since we've implemented steps to keep our costs in check, our overall headcount is down roughly 12% versus a year ago; that should bring additional gains to the operating margin line as the year progresses.
Eve Burstein
analystAt the start of this week, the FDA came out with a final rule that extends its regulatory authority to lab developed tests. In your case, you're fortunate to already have IVD compliant instruments, whereas many of the newer companies trying to compete with you don't have them yet. That said, as we understand it, research use only machines are in fact utilized fairly often for tests that carry FDA approval. It's somewhat more difficult, but it's achievable. So our expectation isn't that this will impact you much or hand you a significant edge over rivals. Is that the correct way to view it? Or might there be additional upside in this for you?
Jacob Thaysen
executiveYes. No, to begin with, we're definitely glad that we now have better clarity regarding the FDA ruling and where this is heading. Even so, plenty of specifics still need to be worked out. But on the whole, you're correct that given how we're positioned — through our DX portfolio as well as the money we've put into high quality and into assisting with the documentation our customers need in order to secure their PMAs — we're in a very strong spot. You brought up that LDTs get used for FDA approval. Well, that's truly only the case when you're operating under a single site PMA arrangement. And that demands a great deal of effort from vendors such as Illumina to assist our customers with it, providing the proper documentation and so forth. So I believe this actually aligns with our strengths moving forward, and we're dedicated to backing this space and enabling our customers to succeed, regardless of whether it's a full PMA at a single site or other kinds of possibilities that this new landscape will present to us.
Conor McNamara
analystI realize you said you wouldn't go into great depth regarding how consumables are being adopted by X customers. However, is there any way you could put a figure on it — among the roughly 400 boxes that have been placed, what portion of those buyers would you describe as being at scale and purchasing in line with what you'd expect from them, compared with those who are still validating or who, because of economic conditions, haven't really ordered as much as you'd anticipated? And on the flip side, have any stock orders come in from any of the X customers?
Jacob Thaysen
executiveYeah, that's a fair question; and right now, we continue to observe that the majority of our customers remain in the ramp phase. Naturally, there are research customers who adopt us very quickly and genuinely operate larger programs. We've observed the <<inaudible>>, we've observed single cell as being certain components or areas where there's been considerable interest in running. And I believe we've seen a few of those research customers already reach scale, at minimum with one of the instruments they purchased, and perhaps now they're beginning to progress to the next one. But on the other hand, when you consider the broader 400, I'd say the general picture is still that this remains in a ramp positioning. So — yes, that's where things stand at the moment.
Joydeep Goswami
executiveAnd the stocking?
Jacob Thaysen
executiveYes, yes, go ahead, Joydeep.
Joydeep Goswami
executiveSo regarding inventory build-up, I'd say with the 25B, we really haven't observed much stocking activity, since its standard initial shelf life tends to be shorter — meaning you wouldn't really anticipate significant stockpiling there. As for the 10B, that stock-up period is still at a very early stage. Once again, we do anticipate seeing somewhat more of it as the year progresses, though it hasn't happened yet.
Sallilyn Schwartz
executiveWe appreciate you being with us on this call. Just a note that you can find a replay in the Investors area of our site. That wraps things up for today, and we hope to connect with you at the conferences and other events we have coming up.
Operator
operatorThis concludes today's call. You may now disconnect.
Read the full transcript via the API
You're viewing the first half of this call. Get the complete Illumina, Inc. transcript — plus 132,000+ transcripts from 7,000+ companies, speaker segments, AI summaries and full-text search — through the EarningsCalls.dev API.
Get the API View API docs →This call discussed
For developers and AI pipelines
Programmatic access to Illumina, Inc. earnings transcripts and 132,000+ others is available through the
EarningsCalls.dev REST API. Plans from $39.99/month — full transcripts, speaker segments,
full-text search, and the recently-added /api/v1/transcripts/recent polling endpoint for ETL pipelines.
More tools for stock research
OptionsBell: an unusual options activity scanner that tracks options flow across all US stocks and emails you when large trades appear in Illumina, Inc. or any ticker on your watchlist.
StockMarketScan: a stock screener with alerts: 24 pre-built screens refreshed every 5 minutes, watchlists and email notifications. Both offer API and MCP access and fair monthly pricing.